Furthermore, we identified a novel combinatorial treatment using KCZ and BZA, which synergizes to reduce cell viability of HER2-enriched breast cancer cells and TNBC cells, suppress breast CSCs, decrease basal primary breast tumor growth using a patient-derived xenograft (PDX) model, and reduce metastatic burden using a TNBC intracardiac mouse model. This evidence concerns the gene ERBB2 and breast carcinoma.